RxDoctor Payments Data

Justin Noroyan, DO

Internal Medicine · Farmington Hills, MINPI 1083053391

Payments from drug & device makers

$7,701in general payments, 2019–2025

Across 443 payments — averaging $17.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AbbVie$898
  • Lilly USA, LLC$823
  • Amgen$664
  • Pfizer$585
  • AstraZeneca$490
  • plus $3K from 42 others

What the payments were for

  • Food & beverage$7,55698%
  • Education$1452%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,701 in reported general payments places this provider in the 90th percentile of 4,567 internal medicine providers in Michigan.

See all internal medicine providers in Michigan

Medicare billing

Part B allowed, 2024
$56,442
Medicare patients
109
Services billed
1,666

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban81$78,246
MounjaroTirzepatide60$69,367
JardianceEmpagliflozin41$40,545
Repatha SureclickEvolocumab32$28,595
TrulicityDulaglutide27$27,363
Trelegy ElliptaFluticasone/Umeclidin/Vilanter40$26,105
XareltoRivaroxaban12$18,897
RybelsusSemaglutide11$16,552
FarxigaDapagliflozin Propanediol13$9,984
JanuviaSitagliptin Phosphate16$8,913
BelsomraSuvorexant16$7,558
LinzessLinaclotide14$7,462
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen140$2,929
Lantus SolostarInsulin Glargine,hum.Rec.Anlog12$2,862
Atorvastatin Calcium208$2,488

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$823$96,72987 claims
PfizerEliquis, Paxlovid$585$79,57792 claims
Boehringer IngelheimJardiance$280$40,54541 claims
GSKTrelegy Ellipta$309$26,10540 claims
Johnson & JohnsonXarelto$203$18,89712 claims
Novo NordiskRybelsus$1,082$16,55211 claims
MerckJanuvia, Belsomra$56$16,47232 claims
AstraZenecaFarxiga$490$9,98413 claims
AbbVieLinzess$898$7,46214 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,567 internal medicine providers in Michigan.

Other internal medicine in Farmington Hills

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →